Parabilis Medicines, Inc. announced that its Chief Medical Officer, Fawzi Benzaghou, M.D., mutually agreed to transition from the company effective September 30, 2026. Dr. Benzaghou will receive severance benefits in accordance with his employment agreement. Parabilis Medicines operates as a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.

Parabilis Medicines, Inc. expanded its Board of Directors to nine members by appointing Craig Tendler as a Class II director effective August 22, 2026. Mr. Tendler will serve until the 2028 annual meeting and join the Science & Technology Committee. He received an equity award comprising a stock option for 20,294 shares at $39.36 per share, vesting over three years, along with an annual retainer of $47,500 ($40,000 base plus $7,500 committee service). Dr. Tendler brings extensive oncology drug development experience from Johnson & Johnson and continues his role as a scientific advisor to the company. Parabilis Medicines is a clinical-stage biopharmaceutical company developing Helicon therapeutics for serious diseases.

Parabilis Medicines reported second quarter 2026 financial results and business updates. The company announced a strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, receiving $125 million in upfront consideration and equity investment, with potential for up to $2.2 billion in milestone payments plus tiered royalties. Parabilis completed an upsized initial public offering of common stock at $20.00 per share, raising $770.5 million before expenses, and began trading on Nasdaq under the ticker PBLS on June 10, 2026. The company ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, expected to fund operations into 2030. Research and development expenses were $39.4 million, while general and administrative expenses were $11.7 million, resulting in a net loss of $52.5 million for the quarter. The company is a clinical-stage biopharmaceutical company focused on developing medicines that target historically undruggable intracellular proteins using its proprietary Helicon platform.

Parabilis Medicines, Inc. entered into a Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc. for the purchase of 4,166,666 shares of common stock at $18.00 per share, representing 90% of the $20.00 IPO price. The private placement closed on June 11, 2026, and the company's certificate of incorporation and bylaws were amended and restated to authorize 800,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. Parabilis Medicines, Inc. is a biotechnology company focused on developing and commercializing medicines.